Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
KARDIGAN INC (KARD)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$13.86-10.93%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for KARD yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Advancement of clinical trials for therapies | Kardigan is developing unique therapies for cardiovascular diseases. | Intact | No new clinical trials initiated by FY27 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 10, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a higher-risk, cyclical Healthcare name rather than a clearly established durable compounder. The thesis state is insufficient because there is not enough recent financial history, and confidence in the overall evidence is low.
The evidence does not provide a valuation level or a clear account of market expectations, so it is not possible to describe KARD as cheap, fair, or expensive versus peers. No fragility gates fired, which indicates no identified pricing fragility in the available signals, but it does not establish what expectations are already priced in.
Near term, repeated earnings misses and the most recent miss point to elevated risk of another miss next quarter. Management is labeled stable, but the President transition is a recent change to watch. Over the multi-year view, the Healthcare sector is a tailwind, though the evidence does not show enough company-level financial history to assess the underlying trajectory.
Near term, a weakening jobs trend could raise recession concerns and weigh more heavily on cyclical names like KARD. The multi-year view also hinges on Healthcare bellwethers such as VRTX, REGN, and MRNA: continued strong results and higher guidance could support sector momentum, while misses or lower guidance could weaken that tailwind.
Over the next 1 to 3 years, KARD’s thesis remains uncertain: sector support is positive, but recent earnings misses and elevated risk leave execution as a key concern. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in KARDIGAN INC's published investment case. The stated target is Secure at least $50 million in funding by FY27. |
| Intact |
| Fail to secure $50 million in funding by FY27 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Obtain regulatory approval for at least one therapy | A primary condition in KARDIGAN INC's published investment case. The stated target is Achieve regulatory approval by FY28. | Intact | Failure to obtain regulatory approval by FY28 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.15 → $-3.68 · observed estimates
Unavailable → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-08-27 | $-3.15 | Unavailable | 2 / 0 |
| 2026-08-28 | $-3.15 | Unavailable | 2 / 0 |
| 2026-08-29 | $-3.35 | Unavailable | 2 / 0 |
| 2026-08-30 | $-3.35 | Unavailable | 2 / 0 |
| 2026-08-31 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-01 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-02 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-03 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-04 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-05 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-06 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-07 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-08 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-09 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-10 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-11 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-12 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-13 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-14 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-15 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-16 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-17 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-18 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-19 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-20 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-21 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-22 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-23 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-24 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-25 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-26 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-27 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-28 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-29 | $-3.35 | Unavailable | 2 / 0 |
| 2026-09-30 | $-3.35 | Unavailable | 2 / 0 |
| 2026-10-01 | $-3.35 | Unavailable | 2 / 0 |
| 2026-10-02 | $-3.35 | Unavailable | 2 / 0 |
| 2026-10-03 | $-3.35 | Unavailable | 2 / 0 |
| 2026-10-04 | $-3.35 | Unavailable | 2 / 0 |
| 2026-10-05 | $-3.35 | Unavailable | 2 / 0 |
| 2026-10-06 | $-3.35 | Unavailable | 2 / 0 |
| 2026-10-07 | $-3.35 | Unavailable | 2 / 0 |
| 2026-10-08 | $-3.35 | Unavailable | 2 / 0 |
| 2026-10-09 | $-3.35 | Unavailable | 2 / 0 |
| 2026-10-10 | $-3.35 | Unavailable | 2 / 0 |
| 2026-10-11 | $-3.35 | Unavailable | 2 / 0 |
| 2026-10-12 | $-3.35 | Unavailable | 2 / 0 |
| 2026-10-13 | $-3.35 | $750,000 | 3 / 4 |
| 2026-10-14 | $-3.35 | $750,000 | 3 / 4 |
| 2026-10-15 | $-3.35 | $750,000 | 3 / 4 |
| 2026-10-16 | $-3.35 | $750,000 | 3 / 4 |
| 2026-10-17 | $-3.35 | $750,000 | 3 / 4 |
| 2026-10-18 | $-3.35 | $600,000 | 3 / 5 |
| 2026-10-19 | $-3.35 | $600,000 | 3 / 5 |
| 2026-10-20 | $-3.35 | $600,000 | 3 / 5 |
| 2026-10-21 | $-7.13 | $600,000 | 4 / 5 |
| 2026-10-22 | $-7.13 | $600,000 | 4 / 5 |
| 2026-10-23 | $-7.13 | $600,000 | 4 / 5 |
| 2026-10-24 | $-7.13 | $500,000 | 4 / 6 |
| 2026-10-25 | $-3.59 | $500,000 | 4 / 6 |
| 2026-10-26 | $-3.59 | $500,000 | 4 / 6 |
| 2026-10-27 | $-3.59 | $500,000 | 4 / 6 |
| 2026-10-28 | $-3.59 | $500,000 | 4 / 6 |
| 2026-10-29 | $-3.59 | $500,000 | 4 / 6 |
| 2026-10-30 | $-3.59 | $500,000 | 4 / 6 |
| 2026-10-31 | $-3.59 | $500,000 | 4 / 6 |
| 2026-11-01 | $-3.59 | $500,000 | 4 / 6 |
| 2026-11-02 | $-3.68 | $428,570 | 5 / 6 |
| 2026-11-03 | $-3.68 | $428,570 | 5 / 7 |
| 2026-11-04 | $-3.68 | $428,570 | 5 / 7 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 8 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 3 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.